Top Markets
#1 CoW Protocol CoW Protocol +58.99%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +39.63%
#4 Walrus Walrus +29.20%
#5 Tutorial Tutorial +18.65%
#6 Cysic Cysic +18.33%
#7 The Black Bull The Black Bull +16.56%
#8 Humanity Humanity +16.53%
#9 龙虾 (Lobster) 龙虾 (Lobster) +15.13%
#10 Velvet Velvet +15.00%
Coin of the day
CoW Protocol CoW Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Stemcell Holdings, Inc. Stemcell Holdings, Inc.

Stemcell Holdings, Inc.

STMM
Rangering i aksjer #37518
Stemcell Holdings, Inc., primarily operating through its subsidiary Stemcell... Stemcell Holdings, Inc., primarily operating through its subsidiary Stemcell Co., Ltd., specializes in the regenerative medicine sector. The company provides crucial technical support for the cultivation, storage, and delivery of stem cells, alongside administrative and consulting services for clinics. It offers two distinct stem cell regenerative therapies: autologous mesenchymal stem cells derived from adipose tissue and natural killer cells. To facilitate its stem cell culturing activities, Stemcell Holdings coordinates patient introductions to clinics, manages scheduling, and provides translation services to overcome language barriers between patients and medical professionals. Additionally, the firm offers internet marketing solutions, specifically search engine optimization for clinics, and engages in property and equipment rental. Founded in Tokyo, Japan, in 2015, the company was formerly known as Perfect Acquisition, Inc. before changing its name to Stemcell Holdings, Inc. in January 2016. As of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.
Aksjekurs
$0.06
Sist synkronisert: 2026-04-08
Markedsverdi
$1.64M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
JP
Handel Stemcell Holdings, Inc. (STMM)

Kategori

Healthcare
P/E-forhold for Stemcell Holdings, Inc. (STMM)
P/E-forhold per 2026 TTM: 0
Ifølge Stemcell Holdings, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Stemcell Holdings, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.